Actionable news
0
All posts from Actionable news
Actionable news in VNDA: Vanda Pharmaceuticals Inc.,

The first of these

prior to the expiration of the 432 Patent in September 2025. This lawsuit is separate from the Companys two pending cases against Roxane relating to the 610 Patent and Aventisub LLCs U.S. Patent No. RE39,198, which are scheduled to be tried together in a four-day bench trial beginning on February29, 2016.

The second of these lawsuits, which was filed against Inventia, seeks an adjudication that Inventia has infringed the 432 Patent by submitting to the FDA an ANDA for a generic version of Fanapt

prior to the expiration of the...


More